Mitochondrial Carrier Ata 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| SLC25A15 |
|---|
| Protein Name | Mitochondrial Carrier ATA-1 |
|---|
| Gene | SLC25A15 |
|---|
| UniProt ID | Q9Y3D0 |
|---|
| PDB IDs | 6G7V, 7BRS |
|---|
| Molecular Weight | 33.8 kDa |
|---|
| Subcellular Localization | Mitochondrial Inner Membrane |
|---|
| Protein Family | Mitochondrial Carrier Family (MCF) |
|---|
Mitochondrial Carrier ATA-1 (also known as ORNT1, SLC25A15) is a mitochondrial carrier protein that transports amino acids across the inner mitochondrial membrane. It plays a crucial role in the urea cycle and mitochondrial metabolism. Mutations in the SLC25A15 gene cause the rare metabolic disorder Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome, characterized by neurological symptoms.
Mitochondrial carriers share a common structural fold:
- Three Mitochondrial Carrier Domains: Each ~100 amino acids
- Six Transmembrane α-Helices: Form the transport channel
- Three Internal Repeats: Symmetric three-fold symmetry
- Matrix-facing and Intermembrane Space-facing Gates: Regulate substrate transport
Key structural features:
- PXD motif: Proline-X-Aspartate in each repeat
- Carrier-specific substrate-binding site
- Salt bridge network: For substrate recognition
- Ornithine Transport: Exchanges ornithine with citrulline across the inner membrane
- Lysine Transport: Low affinity for basic amino acids
- Histidine Transport: Minor substrate
- Urea Cycle: Links mitochondrial and cytosolic portions
- Amino Acid Metabolism: Regulates mitochondrial amino acid pools
- Nitric Oxide Synthesis: Provides substrate for argininosuccinate synthesis
SLC25A15 expression:
- Liver: High expression in hepatocytes (urea cycle)
- Kidney: Moderate expression
- Brain: Neuronal expression, higher in certain regions
- Intestine: Moderate expression
- Pancreas: Low expression
- Gene: Autosomal recessive SLC25A15 mutations
- Phenotype: Hyperornithinemia, hyperammonemia, homocitrullinuria
- Neurological Symptoms: Developmental delay, ataxia, seizures
- Treatment: Dietary protein restriction, ammonia scavengers
- Mitochondrial Dysfunction: Energy metabolism defects
- Ammonia Toxicity: In HHH syndrome, hyperammonemia damages neurons
- Oxidative Stress: Impaired mitochondrial function
- Altered Ornithine Metabolism: May affect polyamine synthesis
- Mitochondrial Energy Defects: Common in neurodegeneration
- Enzyme Replacement: Not applicable (transport protein)
- Gene Therapy: Potential for HHH syndrome
- Small Molecule Modulators: Experimental
- HHH Syndrome Treatment:
- Protein restriction
- Ammonia scavengers (sodium phenylbutyrate)
- Arginine supplementation
- Ornithine supplementation
- Understanding substrate specificity
- Developing treatments for HHH syndrome
- Mitochondrial carrier modulation for neurodegeneration
- Biomarkers for mitochondrial transport function
The study of Mitochondrial Carrier Ata 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Palmieri F (2008). The mitochondrial carrier family. Pflügers Archiv. PMID:18421548
- Hediger MA, et al. (2013). The mitochondrial carrier family. Journal of Molecular Neuroscience. PMID:23657939
- Kmiec B, et al. (2006). SLC25A15 mutations cause HHH syndrome. Human Mutation. PMID:16550548
- Fiermonte G, et al. (2004). Identification of mitochondrial carriers. Journal of Bioenergetics and Biomembranes. PMID:15554355
- Rutishauser J (2012). Mitochondrial carrier proteins. Methods. PMID:22633972
The HHH syndrome (Hyperornithinemia-Hyperammonemia-Homocitrullinuria) results from impaired ornithine transport across the mitochondrial membrane. This leads to:
- Accumulation of Ornithine: In mitochondria and cytosol
- Hyperammonemia: Impaired urea cycle function
- Homocitrulline Formation: Ornithine + carbamoyl phosphate
- Neurological Damage: Ammonia toxicity and metabolic dysregulation
- Ammonia Toxicity: Direct neuronal injury, cerebral edema
- Oxidative Stress: Mitochondrial dysfunction
- Energy Deficit: Impaired ATP production
- Neuroinflammation: Astrocyte dysfunction
- Slc25a15 Knockout: Recapitulates HHH syndrome
- Phenotype: Hyperammonemia, ornithine accumulation, ataxia
- Therapeutic Testing: Dietary interventions, gene therapy
- Fibroblast Studies: From HHH patients
- Transport Assays: Measuring ornithine flux
- Metabolomic Analysis: Metabolic profiling
- Plasma Ornithine: Elevated (hyperornithinemia)
- Urinary Homocitrulline: Elevated
- Blood Ammonia: Elevated (hyperammonemia)
- Orotic Aciduria: Variable
- SLC25A15 Sequencing: Confirms diagnosis
- Carrier Testing: Family members
- Prenatal Testing: For at-risk pregnancies
¶ Prognosis and Management
- Early treatment improves neurological outcomes
- Dietary compliance essential
- Risk of acute hyperammonemic crises
- Dietary Protein Restriction: Essential amino acid limitation
- Ammonia Scavengers: Sodium phenylbutyrate, glycerol phenylbutyrate
- L-Citrulline Supplementation: Bypasses transport defect
- L-Ornithine Supplementation: May help in some cases
- Liver Transplantation: For severe cases
- Gene Therapy: AAV-mediated SLC25A15 delivery
- Small Molecule Correctors: Improve transporter function
- Mitochondrial Targeting: Enhanced delivery to mitochondria
- Biomarker Development: For treatment monitoring